Aethlon Medical (NASDAQ:AEMD) Stock Price Crosses Below 200-Day Moving Average – Here’s What Happened
by Tristan Rich · The Markets DailyAethlon Medical, Inc. (NASDAQ:AEMD – Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $8.19 and traded as low as $2.42. Aethlon Medical shares last traded at $2.46, with a volume of 87,377 shares trading hands.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $560.00.
View Our Latest Stock Report on Aethlon Medical
Aethlon Medical Stock Performance
The firm has a market cap of $2.31 million, a PE ratio of -0.11 and a beta of 1.60. The company’s 50-day simple moving average is $3.57 and its two-hundred day simple moving average is $8.06.
Aethlon Medical (NASDAQ:AEMD – Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The medical equipment provider reported ($3.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.70) by ($2.04). On average, analysts expect that Aethlon Medical, Inc. will post -0.73 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent SEC filing. 1.99% of the stock is owned by institutional investors and hedge funds.
About Aethlon Medical
Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.
The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.